Your Health, We Care
Release date: 2024-11-11 16:51:13 Recommended: 177
Capmatinib has shown significant efficacy in the treatment of non-small cell lung cancer (NSCLC) with mutations in MET exon 14, and its side effects are relatively manageable. The following are more detailed data from pilot studies based on high-authority sources to support the efficacy and side effects of capmatinib:
Based on the final results of the GEOMETRY mono-1 study, capmatinib demonstrated an ORR of up to 68% in treatment-naïve METex14-mutant NSCLC patients. This data suggests that capmatinib is effective in shrinking or disappearing tumors.
For previously treated patients with METex14-mutant NSCLC, capmatinib had an ORR of 44% and an ORR of 52% in second-line therapy. This shows that capmatinib also has some efficacy in treatment-experienced patients.
In treatment-naïve patients, capmatinib has a DCR of 98%, meaning that the vast majority of patients have controlled disease without disease progression.
The DCR of 82% in treatment-experienced patients also demonstrated the effectiveness of capmatinib in controlling disease progression.
The median progression-free survival (PFS) and median overall survival (OS) of treatment-naïve patients was 12.5 months and 21.4 months.
The median PFS and OS of treatment-experienced patients were 5.5 months and 16.8 months. In particular, second-line patients achieved OS of 26.0 months, demonstrating the potential of capmatinib to prolong survival.
According to data from the GEOMETRY mono-1 study, the most common adverse reactions in capmatinib treatment included peripheral edema (47%), nausea (35%), increased serum creatinine (21%), and vomiting (20%). Most of these adverse effects are mild to moderate and can be managed with dose adjustment or discontinuation of treatment.
Grade 3 to 4 serious adverse events were reported in 44% of patients, with dyspnea being the most common (5% of patients). However, most serious adverse events were manageable, and no new safety signals were reported in the studies.
Of all treated patients, four (1%) experienced treatment-related deaths, due to cardiac arrest, hepatitis, organizing pneumonia, and pneumonia, respectively. While these events are serious, their incidence is relatively low.
Capmatinib has shown remarkable efficacy in the treatment of non-small cell lung cancer with MET exon 14 mutations, and its side effects are relatively manageable. These data provide strong support for capmatinib as a targeted therapy option for this patient population. However, patients still need to be closely monitored for adverse effects when receiving capmatinib therapy, and dose adjustments or interruptions of treatment should be made under the guidance of a physician to ensure safety.
